Natural Killer Cells in Older Patients With Acute Myeloid Leukemia
RATIONALE: Studying natural killer cells in samples of blood from patients with cancer may help doctors find out how these cells are effected by chemotherapy.
PURPOSE: This clinical trial is studying natural killer cells in older patients with acute myeloid leukemia.
|Study Design:||Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Descriptive Study Evaluating the Presence and Function of Natural Killer Cells in Elderly Patients With Acute Myeloid Leukemia in First Remission.|
- Evolution of functional natural killer (NK) cells after chemotherapy [ Designated as safety issue: No ]
- Kinetics of NK cells [ Designated as safety issue: No ]
- Activation markers of NK cells [ Designated as safety issue: No ]
|Study Start Date:||November 2006|
|Primary Completion Date:||May 2011 (Final data collection date for primary outcome measure)|
- Determine the evolution of functional receptors of natural killer (NK) cells after completion of chemotherapy in elderly patients with acute myeloid leukemia in first remission.
- Measure the kinetics of cytotoxic functional recovery of NK cells.
- Determine activation markers of NK cells.
OUTLINE: This is a multicenter study.
Patients receive 1 course of consolidation therapy comprising an anthracycline and cytarabine to induce first remission.
Blood is collected on day 0 of the consolidation course and then every 2 weeks for 8 weeks.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00540956
|Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes|
|Marseille, France, 13273|
|Investigator:||Norbert Vey, MD||Institut Paoli-Calmettes|